dragon pharma retatrutide GLP-3: RT Reta | High Purity (Laboratory

Results were presented at the 2025 EASD meeting and published in The New England Journal of Medicine

We estimate that roughly half of people affected by obesity in the US will be eligible to benefit from GLP-1s overall, around 50 million people

The results showed that tirzepatide led to significant and sustained reductions in body weight

For diabetes patients, A1c reductions of approximately 1.0-1.5 percentage points are common with GLP-1 receptor agonists, while tirzepatide has shown reductions of up to 2.0-2.3 percentage points in clinical trials

Safety and Legitimacy I dont know if Found intentionally makes its pricing vague or if its just not great at messaging, but it doesnt help the trust factor when it is so hard to determine actual costs